An experimental multiple sclerosis pill the drug giant Sanofi has touted as one of its big research hopes reduced the number of lesions in a 130-patient study.
The drug, known as SAR442168, works by inhibiting a cellular signal called Bruton’s tyrosine kinase (BTK), which is also the target of the best-selling cancer drug Imbruvica. Unlike other BTK inhibitors, the Sanofi drug can get through the so-called blood-brain barrier into the brain, making it potentially useful in MS.
About the Author Reprints
